Literature DB >> 22560554

Using generalized equivalent uniform dose atlases to combine and analyze prospective dosimetric and radiation pneumonitis data from 2 non-small cell lung cancer dose escalation protocols.

Fan Liu1, Ellen D Yorke, José S A Belderbos, Gerben R Borst, Kenneth E Rosenzweig, Joos V Lebesque, Andrew Jackson.   

Abstract

PURPOSE: To demonstrate the use of generalized equivalent uniform dose (gEUD) atlas for data pooling in radiation pneumonitis (RP) modeling, to determine the dependence of RP on gEUD, to study the consistency between data sets, and to verify the increased statistical power of the combination. METHODS AND MATERIALS: Patients enrolled in prospective phase I/II dose escalation studies of radiation therapy of non-small cell lung cancer at Memorial Sloan-Kettering Cancer Center (MSKCC) (78 pts) and the Netherlands Cancer Institute (NKI) (86 pts) were included; 10 (13%) and 14 (17%) experienced RP requiring steroids (RPS) within 6 months after treatment. gEUD was calculated from dose-volume histograms. Atlases for each data set were created using 1-Gy steps from exact gEUDs and RPS data. The Lyman-Kutcher-Burman model was fit to the atlas and exact gEUD data. Heterogeneity and inconsistency statistics for the fitted parameters were computed. gEUD maps of the probability of RPS rate≥20% were plotted.
RESULTS: The 2 data sets were homogeneous and consistent. The best fit values of the volume effect parameter a were small, with upper 95% confidence limit around 1.0 in the joint data. The likelihood profiles around the best fit a values were flat in all cases, making determination of the best fit a weak. All confidence intervals (CIs) were narrower in the joint than in the individual data sets. The minimum P value for correlations of gEUD with RPS in the joint data was .002, compared with P=.01 and .05 for MSKCC and NKI data sets, respectively. gEUD maps showed that at small a, RPS risk increases with gEUD.
CONCLUSIONS: The atlas can be used to combine gEUD and RPS information from different institutions and model gEUD dependence of RPS. RPS has a large volume effect with the mean dose model barely included in the 95% CI. Data pooling increased statistical power.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22560554      PMCID: PMC3586556          DOI: 10.1016/j.ijrobp.2012.03.024

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  19 in total

Review 1.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

2.  Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study.

Authors:  Ellen D Yorke; Andrew Jackson; Kenneth E Rosenzweig; Louise Braban; Steven A Leibel; C Clifton Ling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-06-04       Impact factor: 7.038

Review 3.  The linear-quadratic transformation of dose-volume histograms in fractionated radiotherapy.

Authors:  T E Wheldon; C Deehan; E G Wheldon; A Barrett
Journal:  Radiother Oncol       Date:  1998-03       Impact factor: 6.280

4.  A comprehensive three-dimensional radiation treatment planning system.

Authors:  R Mohan; G Barest; L J Brewster; C S Chui; G J Kutcher; J S Laughlin; Z Fuks
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-08       Impact factor: 7.038

5.  Results of a phase I dose-escalation study using three-dimensional conformal radiotherapy in the treatment of inoperable nonsmall cell lung carcinoma.

Authors:  Kenneth E Rosenzweig; Jana L Fox; Ellen Yorke; Howard Amols; Andrew Jackson; Valerie Rusch; Mark G Kris; Clif C Ling; Steven A Leibel
Journal:  Cancer       Date:  2005-05-15       Impact factor: 6.860

6.  Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC)

Authors:  J D Cox; J Stetz; T F Pajak
Journal:  Int J Radiat Oncol Biol Phys       Date:  1995-03-30       Impact factor: 7.038

7.  Comparing different NTCP models that predict the incidence of radiation pneumonitis. Normal tissue complication probability.

Authors:  Yvette Seppenwoolde; Joos V Lebesque; Katrien de Jaeger; José S A Belderbos; Liesbeth J Boersma; Cees Schilstra; George T Henning; James A Hayman; Mary K Martel; Randall K Ten Haken
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-03-01       Impact factor: 7.038

8.  Dose-volume analysis of lung complications in the radiation treatment of malignant thymoma: a retrospective review.

Authors:  Vitali Moiseenko; Tim Craig; Andrea Bezjak; Jake Van Dyk
Journal:  Radiother Oncol       Date:  2003-06       Impact factor: 6.280

9.  Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria.

Authors:  S Green; G R Weiss
Journal:  Invest New Drugs       Date:  1992-11       Impact factor: 3.850

10.  Evaluation of two dose-volume histogram reduction models for the prediction of radiation pneumonitis.

Authors:  S L Kwa; J C Theuws; A Wagenaar; E M Damen; L J Boersma; P Baas; S H Muller; J V Lebesque
Journal:  Radiother Oncol       Date:  1998-07       Impact factor: 6.280

View more
  7 in total

1.  Dosimetric predictors for acute esophagitis during radiation therapy for lung cancer: Results of a large statewide observational study.

Authors:  Peter Paximadis; Matthew Schipper; Martha Matuszak; Mary Feng; Shruti Jolly; Thomas Boike; Inga Grills; Larry Kestin; Benjamin Movsas; Kent Griffith; Gregory Gustafson; Jean Moran; Teamour Nurushev; Jeffrey Radawski; Lori Pierce; James Hayman
Journal:  Pract Radiat Oncol       Date:  2017-07-19

Review 2.  Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma?

Authors:  Feng-Ming Spring Kong; Vitali Moiseenko; Jing Zhao; Michael T Milano; Ling Li; Andreas Rimner; Shiva Das; X Allen Li; Moyed Miften; ZhongXing Liao; Mary Martel; Soren M Bentzen; Andrew Jackson; Jimm Grimm; Lawrence B Marks; Ellen Yorke
Journal:  Int J Radiat Oncol Biol Phys       Date:  2018-11-26       Impact factor: 8.013

3.  Dosimetric predictors and Lyman normal tissue complication probability model of hematological toxicity in cervical cancer patients with treated with pelvic irradiation.

Authors:  Dandan Wang; Yueju Yin; Qichao Zhou; Zirong Li; Xingmin Ma; Yong Yin; Baosheng Li; Tong Bai; Dapeng Li; Jian Zhu
Journal:  Med Phys       Date:  2021-12-10       Impact factor: 4.506

4.  Using gEUD based plan analysis method to evaluate proton vs. photon plans for lung cancer radiation therapy.

Authors:  Zhiyan Xiao; Wei J Zou; Ting Chen; Ning J Yue; Salma K Jabbour; Rahul Parikh; Miao Zhang
Journal:  J Appl Clin Med Phys       Date:  2018-02-13       Impact factor: 2.102

5.  Transparency in quality of radiotherapy for breast cancer in the Netherlands: a national registration of radiotherapy-parameters.

Authors:  Nansi Maliko; Marcel R Stam; Liesbeth J Boersma; Marie-Jeanne T F D Vrancken Peeters; Michel W J M Wouters; Eline KleinJan; Maurice Mulder; Marion Essers; Coen W Hurkmans; Nina Bijker
Journal:  Radiat Oncol       Date:  2022-04-12       Impact factor: 3.481

6.  Two-and-a-half-year clinical experience with the world's first magnetic resonance image guided radiation therapy system.

Authors:  Benjamin W Fischer-Valuck; Lauren Henke; Olga Green; Rojano Kashani; Sahaja Acharya; Jeffrey D Bradley; Clifford G Robinson; Maria Thomas; Imran Zoberi; Wade Thorstad; Hiram Gay; Jiayi Huang; Michael Roach; Vivian Rodriguez; Lakshmi Santanam; Harold Li; Hua Li; Jessika Contreras; Thomas Mazur; Dennis Hallahan; Jeffrey R Olsen; Parag Parikh; Sasa Mutic; Jeff Michalski
Journal:  Adv Radiat Oncol       Date:  2017-06-01

7.  Selection of external beam radiotherapy approaches for precise and accurate cancer treatment.

Authors:  Hiroki Shirato; Quynh-Thu Le; Keiji Kobashi; Anussara Prayongrat; Seishin Takao; Shinichi Shimizu; Amato Giaccia; Lei Xing; Kikuo Umegaki
Journal:  J Radiat Res       Date:  2018-03-01       Impact factor: 2.724

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.